MAPT and in situ carcinoma: Another study conducted in 2016 by Abner et al. [115] investigated the plasma NDE levels of P-T181-tau, P-S396-tau, Aβ1-42, repressor element 1-silencing transcription factor (REST), and neurogranin (Ng) in both AD patients and cognitively intact subjects (CIS) at 3- to 11-year intervals.